Novartis Reaches Key Milestone for Ianalumab Ahead of FDA Vote
Novartis has achieved a significant development milestone for its drug candidate ianalumab as it approaches a regulatory decision from the FDA.
Stocks · News reference
IMVIONIX Acquires Commercial Rights to BEOVU® from Novartis
IMVIONIX Inc. has acquired the exclusive commercial rights to BEOVU® (brolucizumab-dbll) in the United States and Canada from Novartis.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Idiopathic Inflammatory Myositis Market Set for Strong Growth at 16.8% CAGR Through 2036, Driven by Rising Demand for Targeted Therapies | DelveInsight
The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.
Novartis Presents Two-Year Data for Ianalumab in Sjögren's Disease
Novartis presented two-year clinical data for ianalumab, demonstrating continued improvements in disease activity for patients with Sjögren's disease.
Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth
The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.
Novartis Ranks First in 2026 Access to Medicine Index
Novartis has retained the top position in the 2026 Access to Medicine Index, becoming the first company to rank first across all technical areas since the index began in 2008.
Novartis ranks first place in 2026 Access to Medicine Index
Novartis ranked first place in the 2026 Access to Medicine Index for the second consecutive time, scoring 3.86 out of 5 and becoming the only company to achieve top rankings across all technical areas since the index began in 2008. The company reached 304 million patients in 2025 and has expanded programs for cancer, heart disease, and malaria treatments, including launching Coartem® Baby and advancing next-generation antimalarial KLU156.